Anti-Human ERBB3/ErbB 3 Recombinant Antibody (Seribantumab)

Customer Review

There are currently no Customer reviews or questions for TAB-892. Click the button above to contact us or submit your feedback about this product.

Laura Brown
03.Dec,23

Ideal for ERBB3 Research

The Anti-Human ERBB3 Therapeutic Antibody (Seribantumab) has been excellent for our ERBB3 research. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

Emily Lewis
09.Aug,22

Reliable in Immunoassays

We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for ERBB3 is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

John Carter
26.Sep,21

Consistent and Effective

This antibody has proven to be consistent and effective in our various assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for ERBB3 have been particularly beneficial.

Q&As

1. Is the anti-Human ERBB3 (ErbB-3) therapeutic antibody Seribantumab suitable for use in Western blotting?

   A: Yes, the anti-Human ERBB3 (ErbB-3) therapeutic antibody Seribantumab (TAB-892) is suitable for use in Western blotting. It provides specific binding to ERBB3, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-Human ERBB3 (ErbB-3) therapeutic antibody Seribantumab?

   A: The recommended storage condition for the anti-Human ERBB3 (ErbB-3) therapeutic antibody Seribantumab (TAB-892) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-Human ERBB3 (ErbB-3) therapeutic antibody Seribantumab be used in immunoprecipitation assays?

   A: Yes, the anti-Human ERBB3 (ErbB-3) therapeutic antibody Seribantumab (TAB-892) can be used in immunoprecipitation assays. It provides specific binding to ERBB3, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-Human ERBB3 (ErbB-3) therapeutic antibody Seribantumab effective in ELISA applications?

   A: Yes, the anti-Human ERBB3 (ErbB-3) therapeutic antibody Seribantumab (TAB-892) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of ERBB3.

5. What is the optimal dilution for using the anti-Human ERBB3 (ErbB-3) therapeutic antibody Seribantumab in immunofluorescence?

   A: The optimal dilution for using the anti-Human ERBB3 (ErbB-3) therapeutic antibody Seribantumab (TAB-892) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Candiello, Ermes, et al. "MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis." Molecular Oncology 17.7 (2023): 1280-1301. https://doi.org/10.1002/1878-0261.13408
   The study investigated the role of microRNA 483-3p (miRNA-483-3p) in metastatic colorectal cancer, focusing on its impact on cancer aggressiveness and invasion. Researchers found that overexpression of miRNA-483-3p increased the proliferation, invasiveness, and stem-like properties of cancer cells by downregulating NDRG1, a metastasis suppressor gene. This downregulation led to the activation of the ERBB3/AKT signaling pathway, which is associated with epithelial-mesenchymal transition (EMT) and cancer progression. The study utilized various experimental approaches, including patient-derived xenografts, m-colosphere cultures, and transcriptomic analyses, to demonstrate the mechanistic link between miRNA-483-3p, NDRG1, and ERBB3/AKT signaling in colorectal cancer.
   Creative Biolabs provided the anti-ERBB3 antibody seribantumab (Cat#: TAB-892) used in this study. This antibody was critical for evaluating the role of ERBB3 in miRNA-483-3p-mediated cancer cell invasion and growth. Treatment with MM121 effectively counteracted the invasive growth induced by miRNA-483-3p overexpression, highlighting its potential as a therapeutic agent for targeting ERBB3 in colorectal cancer. The provision of MM121 by Creative Biolabs enabled the researchers to validate the functional significance of ERBB3 activation in the context of miRNA-483-3p overexpression, contributing to the overall findings of the study.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-892, RRID: AB_3112016)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Related Diseases

EGFR Tyrosine Kinase Inhibitor Resistance

Related Signaling Pathways

ErbB Signaling Pathway

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "Seribantumab"

Afuco™ Anti-ERBB3 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-892)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized antibody expressed in CHO binding to human ERBB3.

DrugMonitor™ Anti-Seribantumab Antibody (VS-1224-YC1075)

Seribantumab is a fully human monoclonal antibody targeting Her3 with potential antineoplastic activity, used in trials for NSCLC, colorectal cancer, and other solid tumors. The DrugMonitor™ Anti-Seribantumab Antibody (VS-1224-YC1075) is an anti-drug antibody (ADA) against Seribantumab. This drug-based antibody is raised in mice immunized with the Seribantumab. The anti-Seribantumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Seribantumab in samples.

See other products for "ERBB3"

Select a product category from the dropdown menu below to view related products.